Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
SynopsisP

Stockholders protest Pfizer's drug prices

Jeanne Lenzer
CMAJ July 06, 2004 171 (1) 24-24-a; DOI: https://doi.org/10.1503/cmaj.1040937
Jeanne Lenzer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

A US coalition of 275 faith-based organizations that control an estimated $100 billion in assets is targeting the pricing practices of a number of drug companies. The coalition previously led antiapartheid shareholder movements.

Charging that high drug prices are a “social justice problem,” the Interfaith Center on Corporate Responsibility (ICCR) submitted a proposal to “increase access to Pfizer products” at Pfizer's April 22 annual meeting. Although the proposal was defeated, it did receive 5% of the vote, surpassing the 3% required by the Securities and Exchange Commission to allow a proposal to be reintroduced the following year.

“This alerts the rest of the shareholders that this is a concern,” said Margaret Weber, coordinator of corporate responsibility for the Adrian Dominican Sisters, an ICCR member.

In its proposal, ICCR said price increases accounted for 1/3 of the increased spending on prescription drugs in 2001. The group's resolution sought to have Pfizer “contain the price of increases of its most-prescribed drug to levels equal to or below the annual rate of inflation.”

Pfizer board members unanimously opposed the resolution. Dr. Henry A. McKinnell, Jr., Chairman of Pfizer, who was paid $7 million in 2003 plus stock options and long-term payouts worth roughly $39 million, said groups like ICCR should focus on “disease costs” instead of “drug costs.”

“But if the cost of the cure makes it inaccessible then the cost of the disease only increases,” noted Weber.

The ICCR is also concerned by what it views as undue political influence exerted by the pharmaceutical industry. According to the Center for Responsive Politics, a US political watchdog organization, Pfizer gave $1.8 million in 2002 in soft money and Political Action Committee funds — an increase of 600% from 1992.

ICCR recently backed a proposal demanding a complete accounting of money given to politicians. It stated: “Our company should be using its resources to win in the marketplace through superior products … not because it has superior access to political leaders.”

The proposal, unanimously opposed by Pfizer's board, won 10% of the vote. Pfizer agreed to make the requested disclosures. Pfizer did not respond to interview requests for this article. — Jeanne Lenzer, Kingston, New York

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 171 (1)
CMAJ
Vol. 171, Issue 1
6 Jul 2004
  • Table of Contents
  • Index by author
  • Canadian Adverse Reaction Newsletter (93-100)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Stockholders protest Pfizer's drug prices
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Stockholders protest Pfizer's drug prices
Jeanne Lenzer
CMAJ Jul 2004, 171 (1) 24-24-a; DOI: 10.1503/cmaj.1040937

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Stockholders protest Pfizer's drug prices
Jeanne Lenzer
CMAJ Jul 2004, 171 (1) 24-24-a; DOI: 10.1503/cmaj.1040937
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Drugs: urogenital

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire